BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32327962)

  • 1. Hypothesized and found mechanisms for potentiation of bradykinin actions.
    Mueller S; Paegelow I; Reissmann S
    Signal Transduct; 2006 Feb; 6(1):5-18. PubMed ID: 32327962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP9alpha.
    Mueller S; Gothe R; Siems WD; Vietinghoff G; Paegelow I; Reissmann S
    Peptides; 2005 Jul; 26(7):1235-47. PubMed ID: 15949642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.
    Minshall RD; Tan F; Nakamura F; Rabito SF; Becker RP; Marcic B; Erdös EG
    Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study on the mechanism of bradykinin potentiation induced by bradykinin-potentiating peptide 9a, enalaprilat and kinin-potentiating peptide.
    Rodrigues MS; Schaffel R; Assreuy J
    Eur J Pharmacol; 1992 Jun; 216(3):357-62. PubMed ID: 1330581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the vascular response to kinins by inhibition of myocardial kininases.
    Dendorfer A; Wolfrum S; Schäfer U; Stewart JM; Inamura N; Dominiak P
    Hypertension; 2000 Jan; 35(1 Pt 1):32-7. PubMed ID: 10642271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
    Hecker M; Blaukat A; Bara AT; Müller-Esterl W; Busse R
    Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?
    Tom B; Dendorfer A; Danser AH
    Int J Biochem Cell Biol; 2003 Jun; 35(6):792-801. PubMed ID: 12676166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converting-enzyme inhibitors potentiate bradykinin-induced relaxation in vitro.
    Félétou M; Germain M; Teisseire B
    Am J Physiol; 1992 Mar; 262(3 Pt 2):H839-45. PubMed ID: 1558194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of B1 receptor mediating des-Arg9-BK-induced rat paw oedema by systemic treatment with bacterial endotoxin.
    Campos MM; Souza GE; Calixto JB
    Br J Pharmacol; 1996 Mar; 117(5):793-8. PubMed ID: 8851492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I.
    Greco AJ; Master RG; Fokin A; Baber SR; Kadowitz PJ
    Can J Physiol Pharmacol; 2006 Nov; 84(11):1163-75. PubMed ID: 17218981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
    Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiating mechanism of bradykinin action on smooth muscle by sulfhydryl compounds.
    Iso T; Nishimura K; Oya M; Iwao J
    Eur J Pharmacol; 1979 Mar; 54(3):303-5. PubMed ID: 428428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bradykinin increases catecholamine release via B2 receptors.
    Dendorfer A; Häuser W; Falias D; Dominiak P
    Pflugers Arch; 1996; 432(3 Suppl):R99-106. PubMed ID: 8994550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of RNA synthesis by bradykinin involves both the B1 and B2 receptor subtypes.
    Yau L; Pinsk M; Zahradka P
    Arch Biochem Biophys; 1996 Apr; 328(1):115-21. PubMed ID: 8638919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of renin inhibition and angiotensin converting enzyme inhibition upon bradykinin potentiation.
    Véniant M; Clozel JP; Fischli W
    J Hypertens; 1992 Feb; 10(2):155-60. PubMed ID: 1313478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
    Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
    Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
    Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
    Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats.
    Paula RD; Lima CV; Khosla MC; Santos RA
    Hypertension; 1995 Dec; 26(6 Pt 2):1154-9. PubMed ID: 7498987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation.
    Takahama K; Araki T; Fuchikami J; Kohjimoto Y; Miyata T
    J Pharm Pharmacol; 1996 Oct; 48(10):1027-33. PubMed ID: 8953504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.
    Gohlke P; Kuwer I; Schnell A; Amann K; Mall G; Unger T
    Hypertension; 1997 Jan; 29(1 Pt 2):478-82. PubMed ID: 9039145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.